Currently, little is known about the function of arginine in the homeostasis of the intestinal immune system. This study was conducted to test the hypothesis that dietary arginine supplementation may alter intestinal microbiota and innate immunity in mice. Mice were fed a basal diet (containing 0.93% L-arginine; grams per gram) or the basal diet supplemented with 0.5% L-arginine for 14 d. We studied the composition of intestinal microbiota, the activation of innate immunity, and the expression of toll-like receptors (Tlrs), proinflammatory cytokines, and antimicrobials in the jejunum, ileum, or colon of mice.
Introduction
L-Arginine is not only a building block for proteins but is also a precursor for synthesis of many biologically active molecules with low-molecular-weights, including NO, ornithine, polyamines (putrescine, spermidine, and spermine), creatine, and agmatine (1) . Each of them has physiologic and immunologic functions in vivo. For example, NO is a regulator of gene expression and protein synthesis, as well as a signaling molecule (1) . Thus, dietary supplementation with arginine improves endothelium-dependent relaxation (2) , nutrient metabolism (3), immune responses (4, 5) , brown adipose tissue growth and development (6) , and pregnancy outcomes in mammals, including rats (7), mice (8) , and swine (9) .
The small intestine of most mammals, including mice, pigs, and humans, is the exclusive site for de novo synthesis of citrulline and arginine from glutamine, glutamate, and proline (1) . Results of recent studies indicate that arginine regulates the metabolism of intestinal bacteria (10) and expression of toll-like receptor (Tlr) 7 4 in enterocytes (11) , suggesting a possible role for arginine in modulating the intestinal innate immune system. However, direct evidence for supporting this hypothesis is lacking. We hypothesized that dietary arginine supplementation may alter the intestinal microbiota and innate immunity in animals. To test this hypothesis, we studied intestinal microbiota composition, activation of innate immunity, and expression of Tlrs, proinflammatory cytokines, and antimicrobials in the jejunum, ileum, or colon of mice fed a basal rodent diet supplemented with or without arginine for 14 d.
Methods and Materials
Antibodies. Antibodies against p85 (Sc-1637), phosphorylated protein kinase B (Akt) (Sc7985-R), c-Jun N-terminal protein kinase (JNK) (Sc-571), phosphorylated JNK (Sc-12882), and TLR4 (Sc-10741) were purchased from Santa Cruz Biotechnology. Antibodies against polymeric Ig receptor (pIgR), lysozyme, extracellular signal-regulated kinases 1/2 (ERK1/2) (CST 4695), phosphorylated ERK1/2 (CST 4370), p38 (CST 8690), phosphorylated p38 (CST 4511), and p65 (CST 6956) were purchased from Cell Signaling Technology.
Experimental design. One hundred female ICR (Institute for Cancer Research) mice (aged 6 wk) were purchased from SLAC Laboratory Animal Center. The mice were housed in a pathogen-free mouse colony (temperature, 20-30°C; relative humidity, 45-60%; 12-h light/dark cycle) and had access to food and drinking water ad libitum. Mice were randomly divided into 2 groups (n = 50 per group). Mice in the control group were fed a basal diet ( Table 1 ) (4) containing 0.93% L-arginine (g/g), whereas mice of the arginine group were fed a basal diet supplemented with 0.5% L-arginine (Ajinomoto). Dietary supplementation with 0.5% L-arginine was based on our published studies showing its beneficial effects on improving immunity in vaccine immunized mice (5) . Unlike previous studies (4,12,13), we did not use alanine as an isonitrogenous control because alanine might affect the mouse immune system in vivo (W. K. Ren, unpublished data). The amount of arginine nitrogen added to the diet for the treatment group was only 0.16% (a negligible amount). After 2 wk of arginine supplementation, all mice were killed by CO 2 asphyxiation and exsanguination to collect the jejunum, ileum, and colon, as well as the luminal content of the jejunum and ileum for analysis. We determined the changes of intestinal innate immunity after 2 wk of arginine supplementation because the biologic impacts of arginine supplementation in vivo have been observed at this time point (5, 14, 15) .
This study was performed according to the guidelines of the Laboratory Animal Ethical Commission of the Chinese Academy of Sciences.
Immunoblotting. Western blot analysis was conducted according to a previous study (16) . Briefly, equal amounts of proteins obtained from cytoplasmic or nuclear fractions were separated by a reducing SDS-PAGE electrophoresis. The proteins were transferred onto polyvinylidene difluoride membranes (Millipore) and blocked with 5% nonfat milk in tris-Tween-buffered saline buffer (20 mM tris, pH 7.5, 150 mM NaCl, and 0.1% Tween 20) for 3 h. The primary antibodies were incubated overnight at 4°C; the horseradish peroxidase-conjugated secondary antibodies were subsequently incubated for 1 h at 25°C before development of the blots using the Alpha Imager 2200 software (Alpha Innotech). We quantified the resultant signals and normalized the data to the abundance of proliferating cell nuclear antigen or actin. Proliferating cell nuclear antigen and actin was used as an indicator of nuclear and cytoplasmic protein fractions, respectively.
Luminal content collection and DNA extraction. Luminal content from the jejunum or ileum was collected for DNA extraction and immediately frozen until additional processing. DNA was extracted with the Tiangen stool mini kit (TianGen) according to the instructions of the manufacturer. DNA concentration was determined by spectrophotometry (Nanodrop).
qRT-PCR. Total RNA was isolated from liquid nitrogen-frozen jejunum, ileum, and colon using TRIzol reagent (Invitrogen) and then treated with DNase I (Invitrogen) according to the instructions of the manufacturer. Primers (Supplemental Table 1 ) used in this study were either synthesized according to our previous protocols or designed with Primer 5.0 according to mouse gene sequence. Real-time PCR was performed according to our previous study (12, 17 
Results
Small-intestinal microbiota composition. Arginine supplementation decreased (P < 0.05) the number of Firmicutes in the jejunum or the ileum (Fig. 1A, B) . The abundance of Bacteroidetes in the jejunum or the ileum in argininesupplemented mice was higher (P < 0.05) than the mice that were not administered arginine supplementation (Fig. 1A, B) . Thus, the population of microbes in the jejunum (Fig. 1A) and ileum ( Fig. 1B) was shifted by arginine supplementation to favor 
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the growth of Bacteroidetes (P < 0.05). We also assessed the population of Lactobacillus and Streptococcus (belonging to Firmicutes), as well as Bifidobacterium in the small intestine in control and arginine-supplemented mice. In the jejunum, Lactobacillus was more dominant (P < 0.05) in argininesupplemented mice than that of controls, whereas the numbers of Streptococcus and Bifidobacterium were similar between the 2 groups of mice (Fig. 1C) . In the ileum, arginine supplementation increased (P < 0.05) the abundance of Streptococcus but decreased (P < 0.05) the population of Lactobacillus (Fig. 1D ).
Tlr activation. In the jejunum, arginine supplementation decreased (P < 0.05) the mRNA level of Tlr6, increased (P < 0.05) the mRNA level of Tlr8, and had little effect on expression of other Tlrs, including Tlr4 ( Table 2) . Similarly, arginine supplementation did not affect the abundance of the TLR4 protein in the jejunum ( Fig. 2A, B) . In the ileum, arginine supplementation increased (P < 0.05) mRNA levels of Tlr4, Tlr5, and Tlr8 but had no effect on other Tlrs (Table 2) . Additionally, we determined intestinal expression of myeloid differentiation factor-88, which is a major component of the TLR signaling pathway (18) . Arginine supplementation did not affect the mRNA level of myeloid differentiation factor-88 in the jejunum or ileum (Table 2 ) compared with controls.
NF-kB and phosphoinositide-3 kinase-Akt pathways. Arginine supplementation decreased (P < 0.05) the abundance of p65 protein in the nucleus in the jejunum ( Fig. 2A, B) and ileum (Fig. 2C, D) . Similarly, arginine supplementation reduced (P < 0.05) the abundance of the phosphoinositide-3 kinase (PI3K) and phosphorylated Akt proteins in the jejunum (Fig. 3A, B) and the abundance of phosphorylated Akt protein in the ileum (Fig.  3C, D) . Thus, arginine supplementation inactivated the NFkB, PI3K, and phosphorylated Akt pathways.
MAPK pathway. Arginine supplementation activated (P < 0.05) p38 MAPK in the jejunum based on the ratio of phosphorylated-p38-to-total p38 (Fig. 4A, B) . In contrast, arginine supplementation had no effect on ERK1/2 ( Fig. 4E, F) or JNK (Fig. 4I, J) activation in the jejunum. In the ileum, arginine supplementation inhibited (P < 0.05) the activation of p38 MAPK (Fig. 4C, D) and ERK1/2 (Fig. 4G, H) by lowering the abundance of phosphorylated p38 and phosphorylated ERK1/2 proteins. However, JNK activation occurred to a greater extent (P < 0.05) in arginine-supplemented mice than in the control group (Fig. 4K, L) .
Intestinal proinflammatory cytokines. Arginine supplementation increased (P < 0.05) expression of IFN-g in the jejunum and had no effect on expression of interleukin-1b (Il-1b), Il-17, or tumor necrosis factor-a (Tnf-a) compared with the control group (Fig. 5A) . In the ileum, arginine supplementation promoted (P < 0.05) expression of Il-1b, interferon-g (Ifn-g), and Tnf-a but did not affect expression of Il-17 (Fig. 5B ). Therefore, arginine supplementation enhanced expression of proinflammatory factors in the small intestine.
Intestinal innate immunity. Arginine supplementation increased (P < 0.05) expression of J-chain of secretory IgA (SIgA) in the jejunum and ileum ( Table 3 ) and had little effect on expression of pIgR in the jejunum or ileum (Table 3 ). In addition, arginine supplementation did not affect the abundance of pIgR protein in the jejunum (data not shown). Arginine supplementation also increased (P < 0.05) expression of mucin-2 (Muc-2), Muc-4, cryptdins 1, 4, and 5, cryptdin-related sequence 1c (Crs1c), and RNase angiogenin 4 (Ang4) in the jejunum, but reduced (P < 0.05) expression of Crs4c and secretory group II A phospholipase A2 (Spla2) compared with the control group (Table 3) . Arginine supplementation had no effect on expressions of lysozyme 2 (Lyz2) or regenerating islet-derived 3g (Reg3g) in the jejunum (Table 3 ). In the ileum, arginine supplementation increased (P < 0.05) expression of cryptdins 1, 4, and 5, Crs1c, Reg3g, Lyz2, and Ang4 but had no effect on expression of Muc2, Muc4, Crs4c, or Spla2 (Table 3 ). In the colon, arginine supplementation enhanced (P < 0.05) expression of J-chain but decreased (P < 0.05) expression of Spla2 and Ang4 (Table 3) . Collectively, arginine supplementation promoted expression of factors in intestinal innate immunity.
Discussion
The recent years have witnessed growing interest in the biochemistry, physiology, immunology, and nutrition of arginine (2,3). Available evidence shows that dietary arginine supplementation modulates gene expression, protein synthesis, growth, and health of humans and other animals (5, 12, 19) . However, the impact of arginine supplementation on intestinal immunity remains essentially unknown. Intestinal microbiota and innate immunity are important factors in the maintenance of mucosal homeostasis (20, 21) . In this study, effects of arginine supplementation on the intestinal microbiota and innate immune system were investigated. A number of dietary factors influence the composition of the intestinal microbiota, especially the abundance of Firmicutes and Bacteroidetes, which are the most dominant bacteria in the intestine (22, 23) . Results of the present study indicate that arginine supplementation increases the abundance of Bacteroidetes but decreases the abundance of Firmicutes in the jejunum and ileum. One possible explanation for this observation is that arginine supplementation changes the intestinal microenvironment, leading to changes in intestinal microbiota composition. For example, arginine supplementation regulates the metabolism and utilization of amino acids by small-intestinal bacteria, such as Escherichia coli (10) , which might in turn affect the composition and activity of some microorganisms. Likewise, increased feed intake augments the abundance of Firmicutes in the gut, whereas food deprivation reverses the bacterial balance to favor Bacteroidetes (24, 25) . In the current work, arginine supplementation did not affect feed intake by mice. Arginine is FIGURE 2 Immunoblotting of nuclear p65 and TLR4 protein in the jejunum (A) and nuclear p65 protein in the ileum (C) of mice fed a control or 0.5% L-arginine-supplemented diet for 2 wk. Quantification of relative p65 and TLR4 abundance from data shown in A (B) and relative p65 abundance from data shown in C (D). Values are means 6 SEMs, n = 6. *Different from control, P , 0.05. PCNA, proliferating cell nuclear antigen; TLR4, toll-like receptor 4.
FIGURE 3
Immunoblotting of PI3K and p-Akt protein in the jejunum (A) and ileum (C) of mice fed a control or 0.5% L-arginine-supplemented diet for 2 wk. Quantification of relative PI3K and p-Akt abundance from data shown in A (B) and C (D). Values are means 6 SEMs, n = 6. *Different from control, P , 0.05. p-AKT, phosphorylated protein kinase B; PI3K, phosphoinositide-3 kinase.
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catabolized by bacteria to yield agmatine and polyamines (1), which may affect gene expression in the intestine. At present, the biologic mechanisms responsible for the effect of arginine supplementation on the number of intestinal Bacteroidetes and Firmicutes remain unknown. However, our findings provide new insight into a role for arginine in reducing obesity (2) because Firmicutes play a critical role in the pathogenesis of this metabolic disease (24) .
Enhanced population of Bacteroidetes might affect the intestinal mucosa because they consume glycans released from the mucus, resulting in an intimate interaction between the microbiota and host enterocytes (26) . Thus, it is not surprising to uncover that arginine supplementation also promotes the innate immune response in the small intestine, including expression of the following: 1) TLR proteins; 2) proinflammatory cytokines; 3) factors associated with SIgA production and transportation; and 4) antimicrobial substances produced by goblet cells and Paneth cells. Indeed, changes in the intestinal microbiota have been reported to be associated with alterations in intestinal innate immunity (20) .
The NF-kB pathway plays an important role in activating host proinflammatory responses to the stimulation of Tlrs by intestinal microbes (27) . In general, NF-kB p65 and p50 proteins are sequestered into the cytosol by inhibitory kB protein. After activation, the degradation of IkB proteins allows for p65 and p50 dimers to translocate to the nucleus, in which it can turn on expression of specific genes (e.g., Tnf-a) that have NF-kB-binding elements in their promoters or other sites to produce proinflammatory cytokines (27) . The PI3K-Akt pathway also modulates intestinal innate immunity through regulating FIGURE 4 Immunoblotting of total and phosphorylated p38 MAPK in the jejunum (A) and ileum (C) of mice fed a control or 0.5% L-argininesupplemented diet for 2 wk. The ratio of phosphorylated p38 MAPK abundance to total p38 MAPK abundance from data shown in A (B) and C (D). Immunoblotting of total and phosphorylated ERK1/2 in the jejunum (E) and ileum (G). The ratio of phosphorylated ERK1/2 abundance to total ERK1/2 abundance from data shown in E (F) and G (H). Immunoblotting of total and phosphorylated JNK in the jejunum (I) and ileum (K). The ratio of phosphorylated JNK abundance to total JNK abundance from data shown in I (J) and K (L). Values are means 6 SEMs, n = 6. *Different from control, P , 0.05. ERK1/2, extracellular signal-regulated kinases 1/2; JNK, c-Jun N-terminal protein kinase; P-ERK1/2, phosphorylated extracellular signal-regulated kinases 1/2; P-JNK, phosphorylated c-Jun N-terminal protein kinase; P-P38, phosphorylated p38.
FIGURE 5
Proinflammatory cytokine mRNA levels in the jejunum (A) and ileum (B) of mice fed a control or 0.5% L-arginine-supplemented diet for 2 wk. Values are means 6 SEMs, n = 6. *Different from control, P , 0.05. Ifn-g, interferon-g; Il-1b, interleukin-1b; Il-17, interleukin-17; Tnf-a, tumor necrosis factor-a.
the phosphorylation of inhibitory kB kinases to activate the NF-kB pathway (27) . Besides NF-kB and PI3K-Akt, MAPKs (e.g., p38 MAPK, ERK1/2, and JNK) regulate intestinal innate immunity (27) . In accordance with previous findings (28, 29) , we found that dietary arginine supplementation decreased the activation of multi-signaling pathways, including NF-kB, MAPK, and PI3K-Akt, but not p38 MAPK, in the jejunum and JNK in the ileum (Figs. 2-4 ). This novel observation has important implications for intestinal health because these pathways contribute to the pathogenesis of gut disease (30, 31) . Although arginine supplementation inhibits NF-kB, PI3K-Akt, and p38 MAPK activation, this nutritional treatment promotes expression of intestinal proinflammatory cytokines. Thus, it is interesting to identify the effect of arginine on other signaling pathways involved in intestinal inflammatory responses, such as signal transducer and activator of transcription, PPARg, and activating protein-1. Collectively, these findings aid in explaining beneficial roles for arginine in intestinal health (3) .
J-chain and pIgR play roles in the production and transportation of SIgA, which is key to protecting the gut against bacterial invasion and to maintaining intestinal homeostasis (32, 33) . Expression of Paneth cell-or goblet cell-generated antimicrobial substances was assessed because they are crucial for maintaining intestinal homeostasis (21, 34) . These molecules include a-defensins (cryptdins 1, 4, and 5), Crs1c, Crs4c, Lyz2, Spla2, Reg3g, and Ang4. Arginine supplementation promotes sIgA production and transportation and expression of the key genes for the production of antimicrobials by goblet and Paneth cells. Similarly, other investigators reported that arginine supplementation increases intestinal sIgA amounts in severely burned mice (35) and goblet cell numbers in pigs (36) . Our discovery of a stimulating effect of arginine on Paneth cells has important implications for intestinal and whole-body health because impairment of their function contributes to the pathogenesis of many diseases, such as obesity (37) , inflammatory bowel disease (38) , and enteric infection (39) . Thus, the regulatory role of arginine in the prevention and treatment of these diseases may be mediated in part through Paneth cell activation. Intriguingly, unlike previous reports that IFN-g decreases the production of Paneth-derived antimicrobials in Toxoplasma gondii-infected mice (39), we found that the enhanced expression of T-helper 1 cytokines in the mouse small intestine was consistent with Paneth cell activation (Fig. 5) . One possible reason is that arginine supplementation affects expression of T-helper 2 cytokines, which in turn activate Paneth cells (40) .
Intestinal proinflammatory cytokines (Il-1b, Il-17, Ifn-g, and Tnf-a), whose expression is affected by intestinal microbiota and TLR signaling, play a central role in intestinal inflammatory disease (41) (42) (43) (44) . Additionally, numerous studies demonstrated that intestinal bacterial population and innate immunity can influence each other (20, 21, 33, 38, (45) (46) (47) (48) (49) . Like previous studies (23, 37) , we observed that the change of intestinal bacterial population after arginine supplementation coincides with the activation of intestinal innate immunity. We suggest that a change of intestinal microbiota precedes the activation of intestinal innate immunity because the intestinal microbiota is capable of rapidly adapting to dietary changes (23) .
The effect of dietary arginine supplementation on innate immune responses in the intestine differs among the jejunum, ileum, and colon. This may be related to different microenvironments among the various segments of the gut at molecular and cellular levels (50) (51) (52) . Arginine is mainly absorbed in the proximal region of the small intestine, resulting in little, if any, entry of this amino acid into the colon. Another possible reason is that the intestinal microbiota in the large intestine is more complex than the small intestine, resulting in differences in concentrations of microbial metabolites (for example, shortchain FAs and ammonia) (53) (54) (55) . Future studies are warranted to determine the responses of each intestinal cell type (such as immune cells, epithelial cells, and microbes) to dietary arginine supplementation.
In conclusion, dietary arginine supplementation changes the intestinal microbiota, contributing to the activation of TLR signaling. This, in turn, induces expression of proinflammatory cytokines, production of intestinal sIgA, and activation of goblet cells and Paneth cells through NF-kB, MAPK, and PI3K-phosphorylated-Akt signaling pathways. The effects of arginine supplementation on intestinal microbiota and innate immunity are dependent on the segment of the gut with different populations of bacteria. To our knowledge, this is the first study to investigate the impact of dietary arginine supplementation on intestinal microbiota and innate immunity in animals. Our results aid in enhancing understanding of basic knowledge about the nutrition, physiology, and immunology of arginine.
